|
|
|
|
Manufacturing is a strategic biotech decision, not just sourcing. Scalable vector platforms, distributed production, and flexible manufacturing can reduce costs, ease bottlenecks, and expand patient access.
|
|
|
|
|
Standardized point-of-care manufacturing overcomes cell therapy access, cost, and supply challenges, enabling regional centers to efficiently deliver high-quality treatments.
|
|
|
|
|
Muni Seva Ashram’s Kailash Cancer Hospital and Research Center (KCHRC) in Gujarat is preparing to introduce CAR-T therapy using Vector BioMed’s LENTIVERSE platform, with the first patients expected in 2026 after extensive planning and facility development.
|
|
|
|
|
|
|
Advanced lentiviral vector platforms accelerate cell and gene therapy development, improving product quality, reducing costs, and enabling efficient scale-up from discovery to GMP manufacturing.
|
|
|
|
|
|
|
|
|
|
Established Target? Your Vector Is Already Built.
|
LENTIVERSE™ LaunchSuite pairs engineered lentiviral vectors with integrated reagents and a standardized cell manufacturing workflow, moving from patient starting material to finished CAR-T product in 7 days. Start with 1 mL aliquots, scale to CGMP supply, pre-IND documentation included.
|
|
• Request Information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vector BioMed spun out of Caring Cross to change the relationship therapy developers have with their vector supplier. LENTIVERSE™ is the result: one lentiviral vector platform, two paths to advance cures. LaunchSuite gives clinical institutions a ready-to-deploy route to point-of-care CAR-T on established targets. VectorCraft gives developers of novel therapies a custom vector engineered with the full development path in view. Both draw on decades of hands-on lentiviral vector experience, led by founder Dr. Boro Dropulić. See how LaunchSuite lets you manufacture where care happens, or how a streamlined custom program turns future therapies into product realities. Learn more.
|
|
|
